Search research articles
Contact Us
Filters
Showing results (271-280 of 419) with videos related to
Page
of 42
Sort By:
Urologic Oncology
|
September 12, 2025
Long-term oncologic outcomes of metastatic clear-cell renal cell carcinoma after local therapy alone
Daniel Barbakoff, Mark T Dawidek, Andrea Knezevic, et al.
The Lancet. Oncology
|
December 25, 2019
Transcriptomic signatures related to the obesity paradox in patients with clear cell renal cell carcinoma: a cohort study
Alejandro Sanchez, Helena Furberg, Fengshen Kuo, et al.
Urologic Oncology
|
September 6, 2025
Radiomic biomarkers associated with immune checkpoint blockade response for advanced renal cell carcinoma
Stephen W Reese, Daniel Barbakoff, Burcin Agridag Ucpinar, et al.
Cancer Discovery
|
January 10, 2019
Transcriptomic Profiling of the Tumor Microenvironment Reveals Distinct Subgroups of Clear Cell Renal Cell Cancer: Data from a Randomized Phase III Trial
A Ari Hakimi, Martin H Voss, Fengshen Kuo, et al.
Journal of the National Cancer Institute
|
November 29, 2013
An epidemiologic and genomic investigation into the obesity paradox in renal cell carcinoma
A Ari Hakimi, Helena Furberg, Emily C Zabor, et al.
The Oncologist
|
February 22, 2017
Molecular Subtypes Improve Prognostic Value of International Metastatic Renal Cell Carcinoma Database Consortium Prognostic Model
Guillermo de Velasco, Aedín C Culhane, André P Fay, et al.
Kidney Cancer (Clifton, Va.)
|
October 19, 2018
Genomic Alterations and Outcomes with VEGF-Targeted Therapy in Patients with Clear Cell Renal Cell Carcinoma
M I Carlo, B Manley, S Patil, et al.
Journal for Immunotherapy of Cancer
|
October 24, 2018
Safety and efficacy of nivolumab in combination with sunitinib or pazopanib in advanced or metastatic renal cell carcinoma: the CheckMate 016 study
Asim Amin, Elizabeth R Plimack, Marc S Ernstoff, et al.
Journal for Immunotherapy of Cancer
|
March 16, 2019
Correction to: Safety and efficacy of nivolumab in combination with sunitinib or pazopanib in advanced or metastatic renal cell carcinoma: the CheckMate 016 study
Asim Amin, Elizabeth R Plimack, Marc S Ernstoff, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
July 6, 2017
Safety and Efficacy of Nivolumab in Combination With Ipilimumab in Metastatic Renal Cell Carcinoma: The CheckMate 016 Study
Hans J Hammers, Elizabeth R Plimack, Jeffrey R Infante, et al.
Page
of 42
Search research articles
Search
Showing results (271-280 of 419) with videos related to
Sort By:
Page
of 42
Urologic Oncology
|
September 12, 2025
Long-term oncologic outcomes of metastatic clear-cell renal cell carcinoma after local therapy alone
Daniel Barbakoff, Mark T Dawidek, Andrea Knezevic, et al.
The Lancet. Oncology
|
December 25, 2019
Transcriptomic signatures related to the obesity paradox in patients with clear cell renal cell carcinoma: a cohort study
Alejandro Sanchez, Helena Furberg, Fengshen Kuo, et al.
Urologic Oncology
|
September 6, 2025
Radiomic biomarkers associated with immune checkpoint blockade response for advanced renal cell carcinoma
Stephen W Reese, Daniel Barbakoff, Burcin Agridag Ucpinar, et al.
Cancer Discovery
|
January 10, 2019
Transcriptomic Profiling of the Tumor Microenvironment Reveals Distinct Subgroups of Clear Cell Renal Cell Cancer: Data from a Randomized Phase III Trial
A Ari Hakimi, Martin H Voss, Fengshen Kuo, et al.
Journal of the National Cancer Institute
|
November 29, 2013
An epidemiologic and genomic investigation into the obesity paradox in renal cell carcinoma
A Ari Hakimi, Helena Furberg, Emily C Zabor, et al.
The Oncologist
|
February 22, 2017
Molecular Subtypes Improve Prognostic Value of International Metastatic Renal Cell Carcinoma Database Consortium Prognostic Model
Guillermo de Velasco, Aedín C Culhane, André P Fay, et al.
Kidney Cancer (Clifton, Va.)
|
October 19, 2018
Genomic Alterations and Outcomes with VEGF-Targeted Therapy in Patients with Clear Cell Renal Cell Carcinoma
M I Carlo, B Manley, S Patil, et al.
Journal for Immunotherapy of Cancer
|
October 24, 2018
Safety and efficacy of nivolumab in combination with sunitinib or pazopanib in advanced or metastatic renal cell carcinoma: the CheckMate 016 study
Asim Amin, Elizabeth R Plimack, Marc S Ernstoff, et al.
Journal for Immunotherapy of Cancer
|
March 16, 2019
Correction to: Safety and efficacy of nivolumab in combination with sunitinib or pazopanib in advanced or metastatic renal cell carcinoma: the CheckMate 016 study
Asim Amin, Elizabeth R Plimack, Marc S Ernstoff, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
July 6, 2017
Safety and Efficacy of Nivolumab in Combination With Ipilimumab in Metastatic Renal Cell Carcinoma: The CheckMate 016 Study
Hans J Hammers, Elizabeth R Plimack, Jeffrey R Infante, et al.
Page
of 42